Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball

Tschöpe, Carsten; Linthout, Sophie Van; Kherad, Behrouz

doi:10.1007/s11886-017-0874-6

Cited by 23 publications

(34 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MicroRCAs sind kleine, nicht kodierende Ribonukleinsäuren, die über Boten-RNA, die sogenannte Messenger-RNA oder mRNA, mit der Expression bestimmter Gene interagieren. Während davon ausgegangen werden kann, dass auch in der HFpEF bestimmte Mirco-RNA-Signaturen spezifisch verändert sind, ist es bisher (noch) nicht gelungen, dies in einen klinisch relevanten und erfolgreichen Ansatz zu übersetzen [19,20]. Auch das komplexe Feld einer Zelltherapie zielt darauf ab, myokardiale Inflammation und Fibrose bei HFpEF-Patienten zu adressieren.…”

Section: Zytokin-inhibition Micro-rnas Zelltherapieunclassified

See 1 more Smart Citation

Medikamentöse Therapie bei Herzinsuffizienz mit erhaltener Pumpfunktion

Trippel¹,

Tschöpe²

2020

Dtsch Med Wochenschr

Self Cite

View full text Add to dashboard Cite

Die Herzinsuffizienz mit erhaltener Pumpfunktion verläuft prognostisch so bedrohlich wie bösartige Krebserkrankungen, führt zu häufigen Krankenhausaufenthalten und bringt enorme soziale und ökonomische Kosten mit sich. In der symptom-und risikofaktorenbasierten medikamentösen Behandlung werden meist Diuretika, Renin-Angiotensin-Aldosteron-Inhibitoren (RAASi) und ggf. Antidiabetika eingesetzt. Eine kausale Therapie ist nicht etabliert.

show abstract

Section: Zytokin-inhibition Micro-rnas Zelltherapieunclassified

“…Dazu werden aus dem Körper gewonnene bzw. programmierte Zellen zielgerichtet verabreicht, um therapeutische Effekte zu erzielen [19,20]. Jedoch sind die klinischen Effekte auch im Feld der Zelltherapie bisher nicht als bahnbrechend zu bezeichnen.…”

Section: Zytokin-inhibition Micro-rnas Zelltherapieunclassified

Medikamentöse Therapie bei Herzinsuffizienz mit erhaltener Pumpfunktion

Trippel¹,

Tschöpe²

2020

Dtsch Med Wochenschr

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the heart is one of the most highly energy consuming organs, adjuvant therapy, that is aimed at increasing energetic metabolism, possesses cytoprotective and adaptive effects, reduces endothelial dysfunction and has a great potential [25]. Several preparations with antioxidant, anti-inflammatory, antiplatelet and hypolipidemic properties are known [24]. Among the groups of such preparations, succinic acid deserves special attention.…”

Section: Problem Statement and Analysis Of The Latest Researchmentioning

confidence: 99%

Changes in the Levels of Modern Biomarkers in Patients with Decompensated Heart Failure After Myocardial Infarction Under the Influence of Treatment with Succinic Acid and Arginine Preparations

Levandovska

2019

Galician med. j.

View full text Add to dashboard Cite

The prevalence of heart failure in Europe and worldwide is high. This syndrome is a common cause of hospitalization and has a significant impact on morbidity, mortality and healthcare costs in highly developed countries. The study of biomarkers in heart failure is of wide interest as they can improve diagnosis, predict the development of heart failure and its decompensation, and help in assessing treatment outcomes. The objective of the research was to study the feasibility of using multiple biomarker strategy for diagnosing decompensated heart failure in the post-infarction period and to assess changes in these markers after treatment with succinic acid and arginine preparations. Materials and Methods. There were examined 120 patients with Q-QS wave and non-Q wave myocardial infarction complicated by decompensated heart failure. All the patients were divided into 2 groups (depending on Q-QS wave and non-Q wave myocardial infarction) and 4 subgroups (depending on rehabilitation therapy) being homogenous by age and gender. Results. When studying the dynamics of changes in blood level of N-terminal pro-B-type brain natriuretic peptide and ST2, there was observed its significant reduction in all the patients with prior Q-QS wave myocardial infarction complicated by decompensated heart failure after treatment. The most significant changes were observed in the patients of Group IV who, on the background of basic therapy, received succinic acid and arginine preparations according to the proposed scheme. The combined use of arginine preparations and succinic acid in combination therapy for decompensated heart failure secondary to prior Q-QS wave myocardial infarction allowed reducing blood levels of N-terminal pro-B-type brain natriuretic peptide under conditions of graded exercises. Similar tendencies were observed when determining this indicator in the patients with non-Q wave myocardial infarction complicated by decompensated heart failure after rehabilitation treatment. Conclusions. The use of succinic acid and arginine preparations when treating the patients with prior Q-QS wave and non-Q wave myocardial infarction complicated by decompensated heart failure allowed us to significantly reduce the level of immunological enzymes such as N-terminal pro-B-type brain natriuretic peptide and ST2, which indicate the presence and development of decompensated heart failure after myocardial infarction.

show abstract

“…These changes lead to a maladaptive response to stress resulting in the development of fibrosis, heart failure (HF) and fatal arrhythmias [ 29 , 30 ]. From a clinical point of view, heart failure could be classified as heart failure with preserved ejection fraction (HFpEF, i.e., left vetricular ejection fraction (LVEF)>50%), heart failure with reduced ejection fraction (HFrEF, LVEF <40%) and most recently heart failure with mid-range ejection fraction (HFmrEF, LVEF 40–49%) [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

A myriad of roles of miR-25 in health and disease

2018

View full text Add to dashboard Cite

Small non-coding RNAs including microRNAs (miRNAs) have been recently recognized as important regulators of gene expression. MicroRNAs play myriads of roles in physiological processes as well as in the pathogenesis of a number of diseases by translational repression or mRNA destabilization of numerous target genes. The miR-106b-25 cluster is highly conserved in vertebrates and consists of three members including miR-106b, miR-93 and miR-25. MiR-106b and miR-93 share the same seed sequences; however, miR-25 has only a similar seed sequence resulting in different predicted target mRNAs. In this review, we specifically focus on the role of miR-25 in healthy and diseased conditions. Many of miR-25 target mRNAs are involved in biological processes such as cell proliferation, differentiation, and migration, apoptosis, oxidative stress, inflammation, calcium handling, etc. Therefore, it is no surprise that miR-25 has been reported as a key regulator of common cancerous and non-cancerous diseases. MiR-25 plays an important role in the pathogenesis of acute myocardial infarction, left ventricular hypertrophy, heart failure, diabetes mellitus, diabetic nephropathy, tubulointerstitial nephropathy, asthma bronchiale, cerebral ischemia/reperfusion injury, neurodegenerative diseases, schizophrenia, multiple sclerosis, etc. MiR-25 is also a well-described oncogenic miRNA playing a crucial role in the development of many tumor types including brain tumors, lung, breast, ovarian, prostate, thyroid, oesophageal, gastric, colorectal, hepatocellular cancers, etc. In this review, our aim is to discuss the translational therapeutic role of miR-25 in common diseased conditions based on relevant basic research and clinical studies.

show abstract

Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball

Cited by 23 publications

References 111 publications

Medikamentöse Therapie bei Herzinsuffizienz mit erhaltener Pumpfunktion

Medikamentöse Therapie bei Herzinsuffizienz mit erhaltener Pumpfunktion

Changes in the Levels of Modern Biomarkers in Patients with Decompensated Heart Failure After Myocardial Infarction Under the Influence of Treatment with Succinic Acid and Arginine Preparations

A myriad of roles of miR-25 in health and disease

Contact Info

Product

Resources

About